Drug Search Results
More Filters [+]

GSK-2983559

Alternative Names: gsk-2983559, gsk2983559, gsk 2983559
Latest Update: 2023-11-27
Latest Update Note: PubMed Publication

Product Description

GlaxoSmithKline is developing GSK-2983559 as a treatment for inflammatory bowel diseases. (Sourced from: https://classic.clinicaltrials.gov/ct2/show/NCT03358407)

Mechanisms of Action: RIPK2 Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for GSK-2983559

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Inflammatory Bowel Diseases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCT03358407

P1

Terminated

Inflammatory Bowel Diseases

2019-02-19

Recent News Events